AR066145A1 - Derivados de tetrahidrocarbazol como ligandos de receptores acoplados a la proteina g(gpcr),composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos neurologicos o neurodegenerativos,de fertilidad,infecciones por vih,y como agentes antineoplasicos. - Google Patents
Derivados de tetrahidrocarbazol como ligandos de receptores acoplados a la proteina g(gpcr),composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos neurologicos o neurodegenerativos,de fertilidad,infecciones por vih,y como agentes antineoplasicos.Info
- Publication number
- AR066145A1 AR066145A1 ARP080101755A ARP080101755A AR066145A1 AR 066145 A1 AR066145 A1 AR 066145A1 AR P080101755 A ARP080101755 A AR P080101755A AR P080101755 A ARP080101755 A AR P080101755A AR 066145 A1 AR066145 A1 AR 066145A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- group
- independently
- heterocyclylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Reivindicacion 1: Derivado de tetrahidrocarbazol caracterizado porque es de formula (1) donde: (A) V, W se seleccionan en forma independiente entre sí entre el grupo que consiste en =O, =S, =S+O-, H2 unido en forma geminal; R1, R1* cuando está presente forman juntos en forma independiente =O, =S o =S+-O- o son en forma independiente ambos hidrogeno; R2, R3 se seleccionan en forma independiente entre sí entre el grupo que consiste en: (i) hidrogeno, alquilo, alquilo C9-30, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, -NHX1, -NX2X3, -NO2, -OH, =O, -OCF3, -SR, OSO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O) (OH)2, -C(O)-X4, -C(O)O-X5, -C(O)NH-X6, -C(O)NX7X8, -O-X9, O(X10-O)a-H (a = 1, 2, 3, 4, 5), -O(-X11-O)b-X12 (b = 1, 2, 3, 4, 5), -OC(O)-X13, -OC(O)-O-X14, -OC(O)- NHX15, -O-C(O)-NX16X17, -OP(O)(OX18)(OX19), -OSi(X20)(X21)(X22), -OS(O2)-X23, -NHC(O)-NH2, -NHC(O)-X24, -NX25C(O)-X26, -NH-C(O)-O-X27, -NH-C(O)-NH-X28, -NH-C(O)-NX29X30, -NX31-C(O)-O-X32, -NX33-C(O)-NH-X34, -NX35-C(O)-NX36X37, -NHS(O2)-X38, -NX39S(O2)-X40, -S-X41, -S(O)-X42, -S(O2)-X43, -S(O2)NH-X44, -S(O2)NX45X46, -S(O2)O-X47, -P(O)(OX48)(OX49), -Si(X50)(X51)(X52), -C(NH)-NH2, -C(NX53)-NH2, -c(NH)-NHX54, -C(NH)-NX55X56, -C(NX57)-NHX58, -C(NX59)-NX60X61, -NH-C(O)-NH-O-X62, -NHC(O)-NX63-O-X64, -NX65-C(O)-NX66-O-X67, -N(-C(O)-NH-O-X68)2, -N(-C(O)-NX69-O-X70)2, -N(-C(O)-NH-O-X71)(-C(O)-NX72-O-X73), -C(S)-X74, -C(S)-O-X75, -C(S)-NH-X76, -C(S)-NX77X78, -C(O)-NH-O-X79, -C(O)-NX80-O-X81, -C(S)-NH-O-X82, -C(S)-NX83-O-X84, -C(O)NH-NH-X85, -C(O)-NH-NX86X87, -C(O)-NX88-NX89X90, -C(S)-NH-NH-X91, -C(S)-NH-NX92X93, -C(S)-NX94-NX95X96, -C(O)-C(O)-O-X97, -C(O)-C(O)-NH2, -C(O)-C(O)-NHX98, -C(O)-C(O)-NX99X100, -C(S)-C(O)-O-X101, -C(O)-C(S)-O-X102, -C(S)-C(S)-O-X103, -C(S)-c(O)-NH2, -C(S)-C(O)-NHX104, -C(S)-C(O)-NX105X106, -C(S)-C(S)-NH2, -C(S)-C(S)-NHX107, -C(S)-C(S)-NX108X109, -C(O)-C(S)-NH2, -C(O)-C(S)-NHX110, -C(O)-C(S)-NX111X112; donde X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X29, X30, X32, X33, X34, X35, X36, X37, X38, X39, X40, X42, X43, X44, X45, X46, X47, X48, X49, X50, X51, X52, X53, X54, X55, X56, X57, X58, X59, X60, X61, X62, X63, X64, X65, X66, X67, X68, X69, X70, X71, X72, X73, X74, X75, X76, X77, X78, X79, X80, X81, X82, X83, X84, X85, X86, X87, X88, X89, X90, X91, X92, X93, X94, X95, X96, X97, X98, X99, X100, X101, X102, X103, X104, X105, X106, X107, X108, X109, X110, X111, X112 se seleccionan en forma independiente entre sí entre el grupo que consiste en, alquilo, alquilo c9-30, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo y donde como alternativa X7, X8 y/o X16, X17 y/o X29, X30, y/o X36, X37 y/o X45, X46 y/o X55, X56 y/o X60, X61 y/o X77, X78 y/o X86, X87 y/o X89, X90 y/o X92, X93 y/o X95, X96 y/o X99, X100 y/o X105, X106 y/o X108, X109 y/o X111, X112 y/o respectivamente pueden también formar juntos, heterociclilo; donde opcionalmente dichos sustituyentes del grupo de sustituyentes (i) pueden a su vez estar sustituidos en forma independiente entre sí con al menos un sustituyente, idéntico o diferente, seleccionado entre el grupo que consiste en (ii) alquilo, alquilo C9-30, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, -NHX201, -NX202X203, -NO2, -OH, =O, -OCF3, -SH, -OSO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, P(O)(OH)2, -C(O)-X204, -C(O)O-X205, -C(O)NH-X206, -C(O)NX207X208, -O-X209, -O(-X210-O)c-H (c = 1, 2, 3, 4, 5), -O(-X211-O)d-X212 (d = 1, 2, 3, 4, 5), -OC(O)-X213, -OC(O)-O-X214, -OC(O)-NHX215, -O-C(O)-NX216X217, -op(O)(OX218)(OX219), OSi(X220)(X221)(X222), -OS(O2)-X223, -NHC(O)-NH2, -NHC(O)-X224, -NX225C(O)-X226, -NH-C(O)-O-X227, -NH-C(O)-NH-X228, -NH-C(O)-NX229X230, -NX231-C(O)O-X232, -NX233-C(O)-NH-X234, -NX235-C(O)-NX236X237, -NHS(O2)-X238, -NX239S(O2)-X240, -S-X241, S(O)-X242, -S(O2)-X243, -S(O2)NH-X244, S(O2)NX245X246, -S(O2)O-X247, -P(O)(OX248)(OX249), -Si(X250)(X251)(X252), -C(NH)-NH2, -C(NX253)-NH2, -C(NH)-NRX254, -C(NH)-NX255X256, -C(NX257)-NHX258, -C(NX259)-NX260X261, -NH-C(O)-NH-O-X262, -NH-C(O)NX263-O-X264, -NX265-C(O)-NX266-O-X267, -N(-C(O)-NH-O-X268)2, -N(-C(O)-NX269-O-X270)2, -N(-C(O)-NH-O-X271)(-C(O)-NX272-O-X273), -C(S)-X274, -C(S)-C-X275, -C(S)-NH-X276, -C(S)-NX277X278, -C(O)-NH-O-X279, -C(O)-NX280-O-X281, -C(S)-NH-O-X282, -C(S) NX283-O-X284, -C(O)-NH-NH-X285, -C(O)-NH-NX286X287, -C(O)-NX288-NX289X290, -C(S)-NH-NH-X291, -C(S)-NH-NX292X293, -C(S)-NX294-NX295X296, -C(O)-C(O)-O-X297, -C(O)-C(O)-NH2, -C(O)-C(O)-NHX298, -C(O)-C(O)-NX299X300, -C(S)-C(O)-O-X301, C(O)-C(S)-O-X302, -C(S)-C(S)-O-X303, -C(S)-C(O)-NH2, -C(S)-C(O)-NHX304, -C(S)-C(O)-NX305X306, -C(S)-C(S)-NH2, -C(S)-C(S)-NHX307, -C(S)-C(S)-NX308X309, -C(O)-C(S)-NH2, -c(O)-C(S)-NHX310, C(O)-C(S)-NX311X312 donde X201, X202, X203, X204, X205, X206, X207, X208, X209, X210, X211, X212, X213, X214, X215, X216, X217, X218, X219, X220, X221, X222, X223, X224, X225, X226, X227, X228, X229, X230, X231, X232, X233, X234, X235, X236, X237, X238, X239, X240, X241, X242, X243, X244, X245, X246, X247, X248, X249, X250, X251, X252, X253, X254, X255, X256, X257, X258, X259, X260, X261, X262, X263, X264, X265, X266, X267, X268, X269, X270, X271, X272, X273, X274, X275, X276, X277, X278, X279, X280, X281, X282, X283, X284, X285, X286, X287, X288, X289, X290, X291, X292, X293, X294, X295, X296, X297, X298, X299, X300, X301, X302, X303, X304, X305, X306, X307, X308, X309, X310, X311, X312 se seleccionan en forma independiente entre sí entre el grupo que consiste en, alquilo, alquilo c9-30, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo y donde como alternativa X207, X208 y/o X216, X217 y/o X229, X230 y/o X236, X237 y/o X245, X246 y/o X255, X256 y/o X260, X261 y/o X277, X278 y/o X286, X287 y/o X289, X290 y/o X292, X293 y/o X295, X296 y/o X299, X300 y/o X305, X306 y/o X308, X309 y/o X311, X312 y/o respectivamente pueden también formar juntos heterociclilo; donde opcionalmente dichos sustituyentes del grupo de sustituyentes (ii) pueden a su vez estar sustituidos en forma independiente entre sí con al menos un sustituyente, idéntico o diferente, seleccionado entre el grupo que consiste en: (iii) alquilo, alquilo c9-30, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo , arilo, arilalquilo, heteroarilo, heteroarilalquilo, -F, -Cl, -Br, -I, -CN, -CF3, -N3, -NH2, -NHX401, -NX402X403, -NO2, -OH, =O, -OCF3, -SN, -O-SO3H, -OP(O)(OH)2, -CHO, -COOH, -C(O)NH2, -SO3H, -P(O)(OH)2, -C(O)-X404, -C(O)O-X405, -C(O)NH-X406, -C(O)NX407X408, -O-X409, -O(-X410-O)e-H (e = 1, 2, 3, 4, 5), -O(-X411-O)f-X412 (f = 1, 2, 3, 4, 5), -OC(O)-X413, -OC(O)-O-X414, -OC(O)-NHX415, -O-C(O)-NX416X417, OP(O)(OX418)(O419), -OSi(X420)(X421)(X422), -OS(O2)-X423, -NRC(O)-NH2, -NHC(O)-X424, -NX425C(O)-X426, -NH-C(O)-O-X427, -NH-C(O)-NH-X428, -NH-C(O)-NX429X430, -NX431-C(O)-O-X432, -NX433-C(O)-NH-X434, -NX435-C(O)-NX436X437, -NHS(O2)-X438, -NX439S(O2)-X440, -S-X441, -S(O)-X442, -S(O2)-X443, -S(O2)NH-X444, S(O2)NX445X446, -S(O2)O-X447, -P(O)(OX448)(OX449), -Si(X450)(X451)(X452), -C(NH)-NH2, -C(NX453)-NH2, -C(NR)-NHX454, -C(NH)NX455X456, -C(NX457)-NHX458, -C(NX459)-NX460X461, -NH-C(O)-NH-O-X462, -NH-C(O)-NX463-O-X464, -NX465-C(O)-NX466-O-X467, -N(-C(O)-NH-O-X468)2, -N(-C(O)-NX469-O-X470)2, -N(-C(O)-NH-O-X471)(-C(O)-NX472-O-X473), -C(S)-X474, -C(S)-O-X475, -C(S)-NH-X476, -C(S)-NX477X478, -NH-O-X479, -C(Q)-NX480-O-X481, -C(S)-NH-O-X482, -C(S)-NX483-O-X484, -C(O)-NH-NH-X485, -C(O)-NH-NX486X487, -C(O)-NX488-NX489X490, -C(S)-NH-NH-X491, -C(S)-NH-NX492X493, -C(S)-NX494-NX495X496, -C(O)-C(O)-O-X497, -C(O)-C(O)-NH2, -C(O)-C(O)-NHX498, -C(O)-C(O)-NX499X500, C(O)-O-X501, -C(O)-C(S)-O-X502, -C(S)-C(S)-O-X503, -C(S)-C(O)-NH2, -C(S)-C(O)-NHX504, -C(S)-C(O)-NX505X506, -C(S)-C(S)-NH2, -C(S)-C(S)-NHX507, -C(S)-C(S)-NX508X509, -C(O)-C(S)-NH2, -C(O)-C(S)-NHX510, -C(O)-C(S)-NX511X512; donde X401, X402, X403, X404, X405, X406, X407, X408, X409, X410, X411, X412, X413, X414, X415, X416, X417, X418, X419, X420, X421, X422, X423, X424, X425, X426, X427, X428, X429, X430, X431, X432, X433, X434, X435, X436, X437, X438, X439, X440, X441, X442, X443, X444, X445, X446, X447, X448, X449, X450, X451, X452, X453, X454, X455, X456, X457, X458, X459, X460, X461, X462, X463, X464, X465, X466, X467, X468, X469, X470, X471, X472, X473, X474, X475, X476, X477, X478, X479, X480, X481, X482, X483, X484, X485, X486, X487, X488, X489, X490, X491, X492, X493, X494, X495, X496, X497, X498, X499, X500, X501, X502, X503, X504, X505, X506, X507, X508, X509, X510, X511, X512 se seleccionan en forma independiente entre sí entre el grupo que consiste en: alquilo, alquilo c9-30, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo y donde como alternativa X407, X408 y/o X416, X417 y/o X429, X430 y/o X436, X437 y/o X445, X446 y/o X455, X456 y/o X460, X461 y/o X477, X478 y/o X486, X487 y/o X489, X490 y/o X492, X493 y/o X495, X496 y/o X499, X500 y/o X505, X506 y/o X508, X509 y/o X511, X512 y/o respectivamente pueden también formar juntos heterociclilo; n es en forma independiente 0 o 1; con la primera condicion de que si R1, R1* no están presentes (n es 0), R2, R3 no pueden ser hidrogeno al mismo tiempo; con la segunda condicion de que si R1, R1* están presentes (n es 1) y forman juntos en forma independiente =O, =S o =S+-O- o son en forma independiente ambos hidrogeno, R2, R3 no pueden ser hidrogeno al tiempo; con la tercera condicion de que si R1, R1* no están presentes (n es 0), uno de R2, R3 no puede ser hidrogeno al mismo tiempo que el otro de R2, R3 es -C(=NH)-NH2; con la cuarta condicion de que si R1, R1* están presentes (
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91442407P | 2007-04-27 | 2007-04-27 | |
EP07107094A EP1988098A1 (en) | 2007-04-27 | 2007-04-27 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066145A1 true AR066145A1 (es) | 2009-07-29 |
Family
ID=38529386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101755A AR066145A1 (es) | 2007-04-27 | 2008-04-25 | Derivados de tetrahidrocarbazol como ligandos de receptores acoplados a la proteina g(gpcr),composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos neurologicos o neurodegenerativos,de fertilidad,infecciones por vih,y como agentes antineoplasicos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US8148546B2 (es) |
EP (2) | EP1988098A1 (es) |
JP (1) | JP5371956B2 (es) |
KR (1) | KR20100015967A (es) |
CN (1) | CN101668769B (es) |
AR (1) | AR066145A1 (es) |
AU (1) | AU2008244305B2 (es) |
BR (1) | BRPI0810613A2 (es) |
CA (1) | CA2685428A1 (es) |
HK (1) | HK1138601A1 (es) |
IL (1) | IL200851A0 (es) |
MX (1) | MX2009011348A (es) |
NZ (1) | NZ579671A (es) |
RU (1) | RU2497806C9 (es) |
TW (1) | TWI432454B (es) |
UA (1) | UA99618C2 (es) |
WO (1) | WO2008132153A1 (es) |
ZA (1) | ZA200906241B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2095818A1 (en) | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
MX347391B (es) | 2011-01-04 | 2017-04-25 | Novartis Ag | Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd). |
US8748470B2 (en) * | 2011-03-17 | 2014-06-10 | The University Of Chicago | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins |
CN103142593B (zh) * | 2011-03-23 | 2014-07-16 | 浙江理工大学 | 神经激肽受体2的拮抗剂在白血病治疗中的用途 |
CN102139107B (zh) * | 2011-03-23 | 2012-10-03 | 浙江理工大学 | 神经激肽受体拮抗剂在制备抗癌药物中的用途 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2014002052A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
JP6273274B2 (ja) | 2012-06-28 | 2018-01-31 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
EP2867227B1 (en) | 2012-06-28 | 2018-11-21 | Novartis AG | Complement pathway modulators and uses thereof |
JP6155332B2 (ja) | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
CN104603126B (zh) | 2012-06-28 | 2017-05-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
JP6238980B2 (ja) | 2012-07-12 | 2017-11-29 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
CN103864754B (zh) * | 2012-12-10 | 2016-12-21 | 中国科学院上海药物研究所 | 五元唑类杂环化合物及其制备方法、药物组合物和用途 |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
ES2798899T3 (es) * | 2013-02-25 | 2020-12-14 | Novartis Ag | Mutación novedosa del receptor de andrógenos |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
JP6663863B2 (ja) | 2014-06-12 | 2020-03-13 | シーダーズ−サイナイ メディカル センター | がん治療のための組成物及び方法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
EP3463419A4 (en) * | 2016-05-27 | 2020-03-25 | Forsyth Dental Infirmary for Children | COMPOSITIONS AND METHODS FOR TREATING CANCER USING LIPIDAGONISTS AND RECEPTORS THEREOF |
CN109369510A (zh) * | 2018-10-31 | 2019-02-22 | 云南大学 | 具有抗hiv活性的双甲氧基取代咔唑类化合物制备及用途 |
TR201819936A2 (es) * | 2018-12-20 | 2020-07-21 | Hacettepe Ueniversitesi | |
EP4038147A4 (en) * | 2019-10-03 | 2024-02-07 | Caren Pharmaceuticals Inc | COMBINATORIAL HORMONAL THERAPIES AND FORMULATIONS |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN114790166B (zh) * | 2022-04-28 | 2023-06-23 | 周口市公共检验检测中心 | 四氢咔唑类衍生物及其在制备抗肿瘤药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
RU2207340C2 (ru) * | 2001-08-10 | 2003-06-27 | Ципла Лтд. | Способ получения 1,2,3,9-тетрагидро-9-метил-3-[(2-метил-1н-имидазол-1-ил)метил]-4н-карбазол -4-она или его фармацевтически приемлемых солей |
NZ533430A (en) * | 2001-12-14 | 2005-12-23 | Zentaris Gmbh | Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR) |
DE102004033902A1 (de) * | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
-
2007
- 2007-04-27 EP EP07107094A patent/EP1988098A1/en not_active Withdrawn
-
2008
- 2008-04-25 RU RU2009143990/04A patent/RU2497806C9/ru not_active IP Right Cessation
- 2008-04-25 EP EP08749717A patent/EP2150558A1/en not_active Withdrawn
- 2008-04-25 US US12/109,479 patent/US8148546B2/en not_active Expired - Fee Related
- 2008-04-25 CA CA002685428A patent/CA2685428A1/en not_active Abandoned
- 2008-04-25 AU AU2008244305A patent/AU2008244305B2/en not_active Ceased
- 2008-04-25 NZ NZ579671A patent/NZ579671A/xx unknown
- 2008-04-25 BR BRPI0810613A patent/BRPI0810613A2/pt not_active IP Right Cessation
- 2008-04-25 UA UAA200912000A patent/UA99618C2/ru unknown
- 2008-04-25 CN CN200880013673.3A patent/CN101668769B/zh not_active Expired - Fee Related
- 2008-04-25 WO PCT/EP2008/055039 patent/WO2008132153A1/en active Application Filing
- 2008-04-25 KR KR1020097022477A patent/KR20100015967A/ko not_active Application Discontinuation
- 2008-04-25 JP JP2010504702A patent/JP5371956B2/ja not_active Expired - Fee Related
- 2008-04-25 MX MX2009011348A patent/MX2009011348A/es active IP Right Grant
- 2008-04-25 AR ARP080101755A patent/AR066145A1/es unknown
- 2008-04-25 TW TW097115372A patent/TWI432454B/zh not_active IP Right Cessation
-
2009
- 2009-09-09 ZA ZA200906241A patent/ZA200906241B/xx unknown
- 2009-09-10 IL IL200851A patent/IL200851A0/en unknown
-
2010
- 2010-04-21 HK HK10103864.5A patent/HK1138601A1/xx not_active IP Right Cessation
-
2012
- 2012-01-25 US US13/358,055 patent/US8541462B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2008132153A1 (en) | 2008-11-06 |
US8541462B2 (en) | 2013-09-24 |
JP2010525028A (ja) | 2010-07-22 |
RU2497806C2 (ru) | 2013-11-10 |
IL200851A0 (en) | 2010-05-17 |
KR20100015967A (ko) | 2010-02-12 |
TW200909448A (en) | 2009-03-01 |
EP1988098A1 (en) | 2008-11-05 |
CA2685428A1 (en) | 2008-11-06 |
CN101668769A (zh) | 2010-03-10 |
CN101668769B (zh) | 2014-07-02 |
HK1138601A1 (en) | 2010-08-27 |
ZA200906241B (en) | 2010-04-28 |
AU2008244305B2 (en) | 2013-08-01 |
US20120122763A1 (en) | 2012-05-17 |
EP2150558A1 (en) | 2010-02-10 |
UA99618C2 (ru) | 2012-09-10 |
TWI432454B (zh) | 2014-04-01 |
JP5371956B2 (ja) | 2013-12-18 |
RU2497806C9 (ru) | 2014-01-20 |
US8148546B2 (en) | 2012-04-03 |
AU2008244305A1 (en) | 2008-11-06 |
US20090170783A1 (en) | 2009-07-02 |
RU2009143990A (ru) | 2011-06-10 |
MX2009011348A (es) | 2009-11-05 |
BRPI0810613A2 (pt) | 2017-05-09 |
NZ579671A (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066145A1 (es) | Derivados de tetrahidrocarbazol como ligandos de receptores acoplados a la proteina g(gpcr),composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos neurologicos o neurodegenerativos,de fertilidad,infecciones por vih,y como agentes antineoplasicos. | |
AR074410A1 (es) | Derivados de piridopirimidina como inhibidores de autotaxina | |
ES2547124T3 (es) | Inhibidores de autotaxina | |
AR076005A1 (es) | Derivados de piperidina y piperazina inhibidores de autotaxinas, composiciones farmaceuticas que los comprenden, proceso para prepararlos y uso de los mismos en el tratamiento del cancer y otras patologias asociadas. | |
PE20080914A1 (es) | Anticuerpos anti-activina a | |
Smelick et al. | Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development | |
CA2673483C (en) | Compositions of chk1 inhibitors | |
Gust et al. | Optimization of cisplatin for the treatment of hormone dependent tumoral diseases: Part 1: Use of steroidal ligands | |
JP2010525028A5 (es) | ||
HRP20191049T1 (hr) | (11beta, 17beta)-17-hidroksi-11-[4-(metilsulfonil)fenil]-17-(pentalfuorometil)estra-4,9-dien-3-on za uporabu za liječenje bolesti | |
RU2008129683A (ru) | Ингибиторы iap | |
ES2914305T3 (es) | Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma | |
CZ149893A3 (en) | Use of 2-phenyl-3-aroylbenzothiophene derivative for the preparation of a pharmaceutical preparation against loss of bone mass and pharmaceutical preparation in which said derivative is comprised | |
Shinmura | Feature Selection of Singh et al. Microarray Data (12) | |
Stanić | There are exactly 172 connected integral graphs up to 10 vertices. | |
JP2007500729A (ja) | 雄性及び雌性の性機能障害の治療方法 | |
Chen et al. | Magnesium oxide nanotube as novel strategies to enhance the anticancer activity of 5-Fluorouracil | |
McGonigle et al. | Uterine effects of tamoxifen: a prospective study | |
RU2018134045A (ru) | Пролекарства селективного модулятора рецептора прогестерона (sprm) (11.бета.,17.бета.)-17-гидрокси-11-[4-(метилсульфонил)фенил]-17-(пентафторэтил))эстра-4,9-диен-3-она | |
Sousa et al. | Preparation and characterization of the β-cyclodextrin inclusion complex with benzbromarone | |
Bersteind et al. | Pricing and revenue management: present and trends. | |
EP3740191B1 (en) | Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent | |
Nam et al. | Oxoberberine: a promising natural antioxidant in physiological environments | |
RU2010100337A (ru) | ПРОИЗВОДНОЕ 17β-ЦИАНО-19-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, КОТОРЫЕ ВКЛЮЧАЮТ ПРОИЗВОДНОЕ | |
Škrbić et al. | Faculty information system based on open source technologies. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |